Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Hypertriglyceridemia
Conditions
Severe Hypertriglyceridemia
Trial Timeline
Sep 1, 2010 → Nov 1, 2010
NCT ID
NCT01208961About Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g) is a phase 2 stage product being developed by AstraZeneca for Severe Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01208961. Target conditions include Severe Hypertriglyceridemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01208961 | Phase 2 | Completed |
Competing Products
20 competing products in Severe Hypertriglyceridemia